Scott+Scott Attorneys at Law LLP Investigates Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty – REGN
July 01, 2020 11:27 ET
|
Scott+Scott Attorneys at Law LLP
NEW YORK, July 01, 2020 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is investigating whether certain directors...
KYMAB WINS SUPREME COURT CASE AGAINST REGENERON
June 24, 2020 05:29 ET
|
Kymab Group Ltd
KYMAB WINS SUPREME COURT CASE AGAINST REGENERON Landmark UK Supreme Court Decision Invalidates Regeneron Patent Claims Cambridge, UK; 24 June, 2020: Kymab, a clinical-stage biopharmaceutical company...
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Raises Price Target to $14.00
July 31, 2013 09:15 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwired - Jul 31, 2013) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) ("The Company" or "OHR") and raised its...
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Target Price $3.50
October 17, 2012 09:15 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Oct 17, 2012) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") with a twelve month...
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Raises Target Price to $3.50
August 01, 2012 09:15 ET
|
Vista Partners
SAN FRANCISCO, CA--(Marketwire - Aug 1, 2012) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") and raised its...